Commentary on TRALI in leukemia

Mercy Kuriyan1

  • 1Robert Wood Johnson Medical School, New Jeresy 08901, USA. kuriyame@umdnj.edu

Insights

Transfusion-Related Acute Lung Injury (TRALI) is a rare but serious complication of blood transfusions. Recognizing TRALI in pediatric leukemia patients is crucial for prompt diagnosis and management.

Area of Science:

  • Pediatric Hematology
  • Transfusion Medicine
  • Critical Care

Background:

  • Transfusion-Related Acute Lung Injury (TRALI) is a significant cause of transfusion-related morbidity and mortality.
  • TRALI is characterized by acute lung injury following blood product transfusion.
  • Diagnosis of TRALI in pediatric patients, especially those with comorbidities like leukemia, is challenging due to overlapping symptoms and rarity.

Purpose of the Study:

  • To increase awareness of TRALI as a critical differential diagnosis in pediatric patients with acute respiratory distress.
  • To highlight the challenges in diagnosing TRALI in immunocompromised and chronically transfused pediatric populations.
  • To emphasize the importance of recognizing risk factors for TRALI in hematology/oncology patients.

Main Methods:

  • Review of existing literature and case reports on TRALI in pediatric populations.
  • Analysis of clinical presentations and diagnostic difficulties in leukemic children.
  • Discussion of antibody identification challenges and their intermittent presence.

Main Results:

  • Few well-documented cases of pediatric TRALI exist due to underrecognition and diagnostic hurdles.
  • Allo-immunized pediatric patients undergoing chronic transfusions are at a higher risk for TRALI.
  • Delayed diagnosis can impede timely treatment and preventive strategies.

Conclusions:

  • TRALI should be considered in the differential diagnosis of acute respiratory distress in pediatric leukemia patients.
  • Enhanced vigilance and diagnostic awareness are necessary for prompt TRALI detection in this vulnerable group.
  • Understanding risk factors and facilitating early recognition are key to improving outcomes and implementing preventive measures for TRALI.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...